Medikuntza Nuklearra

2019

1. Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively

   Physica Medica, Vol. 65, pp. 143-149

2. Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 7, pp. 1567-1575

3. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

   Radiotherapy and Oncology, Vol. 135, pp. 13-18

4. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT

   European Journal of Cancer Care, Vol. 28, Núm. 5

5. Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma

   Journal of Vascular and Interventional Radiology